Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770

Martina Gentzsch, Hong Y. Ren, Scott A. Houck, Nancy L. Quinney, Deborah M. Cholon, Pattarawut Sopha, Imron G. Chaudhry, Jhuma Das, Nikolay V. Dokholyan, Scott H. Randell, Douglas M. Cyr

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is a lethal recessive genetic disease caused primarily by the F508del mutation in the CF transmembrane conductance regulator (CFTR). The potentiator VX-770 was the first CFTR modulator approved by the FDA for treatment of CF patients with the gating mutation G551D. Orkambi is a drug containing VX-770 and corrector VX809 and is approved for treatment of CF patients homozygous for F508del, which has folding and gating defects. At least 30% of CF patients are heterozygous for the F508del mutation with the other allele encoding for one of many different rare CFTR mutations. Treatment of heterozygous F508del patients with VX-809 and VX-770 has had limited success, so it is important to identify heterozygous patients that respond to CFTR modulator therapy. R117H is a more prevalent rare mutation found in over 2,000 CF patients. In this study we investigated the effectiveness of VX-809/ VX-770 therapy on restoring CFTR function in human bronchial epithelial (HBE) cells from R117H/F508del CF patients. We found that VX-809 stimulated more CFTR activity in R117H/F508del HBEs than in F508del/F508del HBEs. R117H expressed exclusively in immortalized HBEs exhibited a folding defect, was retained in the ER, and degraded prematurely. VX-809 corrected the R117H folding defect and restored channel function. Because R117 is involved in ion conductance, VX-770 acted additively with VX-809 to restore CFTR function in chronically treated R117H/F508del cells. Although treatment of R117H patients with VX-770 has been approved, our studies indicate that Orkambi may be more beneficial for rescue of CFTR function in these patients.

Original languageEnglish (US)
Pages (from-to)L550-L559
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume311
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cystic Fibrosis
Mutation
Therapeutics
ivacaftor
lumacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
Inborn Genetic Diseases
Epithelial Cells
Alleles
Ions
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

Gentzsch, Martina ; Ren, Hong Y. ; Houck, Scott A. ; Quinney, Nancy L. ; Cholon, Deborah M. ; Sopha, Pattarawut ; Chaudhry, Imron G. ; Das, Jhuma ; Dokholyan, Nikolay V. ; Randell, Scott H. ; Cyr, Douglas M. / Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2016 ; Vol. 311, No. 3. pp. L550-L559.
@article{18a8296af1b14693bf0c35db2ac25e80,
title = "Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770",
abstract = "Cystic fibrosis (CF) is a lethal recessive genetic disease caused primarily by the F508del mutation in the CF transmembrane conductance regulator (CFTR). The potentiator VX-770 was the first CFTR modulator approved by the FDA for treatment of CF patients with the gating mutation G551D. Orkambi is a drug containing VX-770 and corrector VX809 and is approved for treatment of CF patients homozygous for F508del, which has folding and gating defects. At least 30{\%} of CF patients are heterozygous for the F508del mutation with the other allele encoding for one of many different rare CFTR mutations. Treatment of heterozygous F508del patients with VX-809 and VX-770 has had limited success, so it is important to identify heterozygous patients that respond to CFTR modulator therapy. R117H is a more prevalent rare mutation found in over 2,000 CF patients. In this study we investigated the effectiveness of VX-809/ VX-770 therapy on restoring CFTR function in human bronchial epithelial (HBE) cells from R117H/F508del CF patients. We found that VX-809 stimulated more CFTR activity in R117H/F508del HBEs than in F508del/F508del HBEs. R117H expressed exclusively in immortalized HBEs exhibited a folding defect, was retained in the ER, and degraded prematurely. VX-809 corrected the R117H folding defect and restored channel function. Because R117 is involved in ion conductance, VX-770 acted additively with VX-809 to restore CFTR function in chronically treated R117H/F508del cells. Although treatment of R117H patients with VX-770 has been approved, our studies indicate that Orkambi may be more beneficial for rescue of CFTR function in these patients.",
author = "Martina Gentzsch and Ren, {Hong Y.} and Houck, {Scott A.} and Quinney, {Nancy L.} and Cholon, {Deborah M.} and Pattarawut Sopha and Chaudhry, {Imron G.} and Jhuma Das and Dokholyan, {Nikolay V.} and Randell, {Scott H.} and Cyr, {Douglas M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1152/ajplung.00186.2016",
language = "English (US)",
volume = "311",
pages = "L550--L559",
journal = "American Journal of Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "3",

}

Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770. / Gentzsch, Martina; Ren, Hong Y.; Houck, Scott A.; Quinney, Nancy L.; Cholon, Deborah M.; Sopha, Pattarawut; Chaudhry, Imron G.; Das, Jhuma; Dokholyan, Nikolay V.; Randell, Scott H.; Cyr, Douglas M.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 311, No. 3, 01.01.2016, p. L550-L559.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770

AU - Gentzsch, Martina

AU - Ren, Hong Y.

AU - Houck, Scott A.

AU - Quinney, Nancy L.

AU - Cholon, Deborah M.

AU - Sopha, Pattarawut

AU - Chaudhry, Imron G.

AU - Das, Jhuma

AU - Dokholyan, Nikolay V.

AU - Randell, Scott H.

AU - Cyr, Douglas M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cystic fibrosis (CF) is a lethal recessive genetic disease caused primarily by the F508del mutation in the CF transmembrane conductance regulator (CFTR). The potentiator VX-770 was the first CFTR modulator approved by the FDA for treatment of CF patients with the gating mutation G551D. Orkambi is a drug containing VX-770 and corrector VX809 and is approved for treatment of CF patients homozygous for F508del, which has folding and gating defects. At least 30% of CF patients are heterozygous for the F508del mutation with the other allele encoding for one of many different rare CFTR mutations. Treatment of heterozygous F508del patients with VX-809 and VX-770 has had limited success, so it is important to identify heterozygous patients that respond to CFTR modulator therapy. R117H is a more prevalent rare mutation found in over 2,000 CF patients. In this study we investigated the effectiveness of VX-809/ VX-770 therapy on restoring CFTR function in human bronchial epithelial (HBE) cells from R117H/F508del CF patients. We found that VX-809 stimulated more CFTR activity in R117H/F508del HBEs than in F508del/F508del HBEs. R117H expressed exclusively in immortalized HBEs exhibited a folding defect, was retained in the ER, and degraded prematurely. VX-809 corrected the R117H folding defect and restored channel function. Because R117 is involved in ion conductance, VX-770 acted additively with VX-809 to restore CFTR function in chronically treated R117H/F508del cells. Although treatment of R117H patients with VX-770 has been approved, our studies indicate that Orkambi may be more beneficial for rescue of CFTR function in these patients.

AB - Cystic fibrosis (CF) is a lethal recessive genetic disease caused primarily by the F508del mutation in the CF transmembrane conductance regulator (CFTR). The potentiator VX-770 was the first CFTR modulator approved by the FDA for treatment of CF patients with the gating mutation G551D. Orkambi is a drug containing VX-770 and corrector VX809 and is approved for treatment of CF patients homozygous for F508del, which has folding and gating defects. At least 30% of CF patients are heterozygous for the F508del mutation with the other allele encoding for one of many different rare CFTR mutations. Treatment of heterozygous F508del patients with VX-809 and VX-770 has had limited success, so it is important to identify heterozygous patients that respond to CFTR modulator therapy. R117H is a more prevalent rare mutation found in over 2,000 CF patients. In this study we investigated the effectiveness of VX-809/ VX-770 therapy on restoring CFTR function in human bronchial epithelial (HBE) cells from R117H/F508del CF patients. We found that VX-809 stimulated more CFTR activity in R117H/F508del HBEs than in F508del/F508del HBEs. R117H expressed exclusively in immortalized HBEs exhibited a folding defect, was retained in the ER, and degraded prematurely. VX-809 corrected the R117H folding defect and restored channel function. Because R117 is involved in ion conductance, VX-770 acted additively with VX-809 to restore CFTR function in chronically treated R117H/F508del cells. Although treatment of R117H patients with VX-770 has been approved, our studies indicate that Orkambi may be more beneficial for rescue of CFTR function in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84986564652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986564652&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00186.2016

DO - 10.1152/ajplung.00186.2016

M3 - Article

C2 - 27402691

AN - SCOPUS:84986564652

VL - 311

SP - L550-L559

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1040-0605

IS - 3

ER -